



EXPRESS MAIL CERTIFICATE

Date 3/4/03 Label No. EV 294036792-45

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

Name (Print) B.W. LEE Signature B.W. Lee

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

RECEIVED  
MAR 10 2003  
TECHNICAL SERVICES

#6/12  
04-08-03

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 4305/1G031 US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Tilo SCHWIENTEK; Henrik CLAUSEN

Serial No.: 10/084,406

Confirmation No.: 8337

Art Unit: 1652

Filed: February 25, 2002

For: UDP-N-Acetylglucosamine:Galactose- $\beta$ 1,3-N-Acetylgalactosamine-a-R(GLcNAc to GalNAc)b1-6 N-Acetylglucosaminyltransferase

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

Serial No. 09/645,192  
M:\4305\1g031us2\JXY0735.DOC

Docket No. 4305/1G031

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed before a first action on the merits has been mailed.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.


It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the

above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: March 3, 2003

ADDA C. GOGORIS  
 27914 for

S. Peter Ludwig  
Registration No. 25,351  
Attorney for Applicant(s)

DARBY & DARBY  
Post Office Box 5257  
New York, NY 10150-5257  
(212) 527-7700



U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

FILED  
SHEET 1 OF 2  
(REV. 7-80)  
MAR 14 2003

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 4305/1G031US2 SERIAL NO: 10/084,406  
APPLICANT: Tilo SCHWIENTEK FILING DATE: February 25, 2002  
Henrik CLAUSEN CONFIRMATION NO: 8337

**U.S. PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
-------------------------------	----------------------------	-------------	-------------	--------------	-----------------	--------------------

**FOREIGN PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION YES NO</u>
-------------------------------	----------------------------	-------------	----------------	--------------	-----------------	-------------------------------

- |  |                |               |    |           |  |  |
|--|----------------|---------------|----|-----------|--|--|
|  | 1. WO 94/07917 | Apr. 14, 1994 | WO | CO7K13/00 |  |  |
|  | 2. WO 90/07000 | Nov. 16, 1989 | WO | C12N15/54 |  |  |

**OTHER REFERENCES**

**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

\*EXAMINER  
INITIALS

- |     |   |
|-----|---|
| 3.  | Asano, M. <i>et al.</i> <i>EMBO J.</i> <u>16</u> :1850-1857, 1997                                   |
| 4.  | Axford, J.S. <i>et al.</i> , <i>Autoimmunity</i> <u>17</u> :157-163, 1994                           |
| 5.  | Breathnach, R. <i>et al.</i> , <i>Ann. Rev. Biochem.</i> <u>50</u> :349-83, 1981                    |
| 6.  | Brew, K. <i>et al.</i> , <i>Biochemistry</i> <u>59</u> :491-97, 1968                                |
| 7.  | D'Agostaro, G. <i>et al.</i> , <i>Eur. J. Biochem.</i> <u>183</u> :211-217, 1989                    |
| 8.  | Fujita-Yamaguchi, Y. <i>et al.</i> , <i>J. Biol. Chem.</i> <u>256</u> (6):2701-2706, March 25, 1981 |
| 9.  | Furukawa, K. <i>et al.</i> , <i>Inter. Immunology</i> <u>2</u> (1):105-112, 1990                    |
| 10. | Gentzsch, M. and Tanner, W. (1996) <i>EMBO J.</i> , <u>15</u> :5752-5759                            |
| 11. | Hollis, G.F. <i>et al.</i> , <i>Biophys Res Comm.</i> <u>162</u> :1069-1075, 1989                   |
| 12. | Keusch, J., <i>et al.</i> , <i>Glycobiology</i> <u>5</u> :365-700, 1995                             |
| 13. | Kobata, A. <i>Eur J. Biochem.</i> <u>209</u> :483-501, 1992   |
| 14. | Kozak, M., <i>Ann Rev Cell Biol.</i> <u>8</u> :197-225, 1992  |
| 15. | Lu, Q., <i>et al.</i> , <i>Develop Biol.</i> <u>18</u> :257-267, 1997                               |
| 16. | Malissard, M., <i>et al.</i> , (1996) <i>Eur J. Biochem.</i> <u>239</u> :340-348                    |
| 17. | Masri, K.A., <i>et al.</i> , (1988) <i>Biochem Res Comm.</i> <u>157</u> :657-663                    |
| 18. | Mengle-Gaw, L., <i>et al.</i> (1985) <i>Biophys Res Comm.</i> <u>176</u> :1269-1276                 |
| 19. | Moscarello M.A., <i>et al.</i> (1991) <i>Biochim Biophys Acta.</i> <u>831</u> :192-200              |
| 20. | Nakazawa, K. <i>et al.</i> (1988) <i>J. Biochem.</i> <u>104</u> :165-168                            |
| 21. | Nakazawa K. <i>et al.</i> (1991) <i>Eur J. Biochem.</i> <u>196</u> :363-368                         |
| 22. | Narimatsu, H. <i>et al.</i> (1986) <i>Proc Natl Acad Sci USA.</i> <u>83</u> :4720-4724              |

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 4305/1G031US2 SERIAL NO: 10/084,406  
APPLICANT: Tilo SCHWIENTEK FILING DATE: February 25, 2002  
Henrik CLAUSEN CONFIRMATION NO: 8337

23. Parquet, M.R. *et al.*, (1984) *Biochem J.* 218:745-751
24. Powell, J.T. and Brew, K. (1974) *Eur J Biochem.* 48:217-228
25. Shaper, J.H. *et al.* (1995) *Glycoconjugate J.* 12:477
26. Shaper, N.L. *et al.* (1986) *Proc Nat'l Acad Sci USA.* 83:1573-1577
27. Shaper, N.L. *et al.* (1988) *J. Biol. Chem.* 263:10420-10428
28. Shaper, N.L. *et al.* (1997) *J. Biol. Chem.* 272:31389-31399
29. Sheares, B.T. and Carlson, D. (1984) *J. Biol. Chem.* 259:8045-8047
30. Shur, B.D. (1982) *J. Biol. Chem.* 257:6871-6878
31. Wilson, I.B. *et al.* (1993) *J. Rheumatol.* 20:1282-1287
32. Johnston, D. *et al.* (1998) *J. Biol. Chem.* 273(4):1888-1895
33. VanDie, I. *et al.* (1997) *Glycobiology*, Letter to the Glyco-Forum, pages v-vii
34. Sato, T. *et al.*, (1988) *Biochem & Biophysical Res. Comm.* 244(3):637-641
35. Almeida *et al.*, *Glycoconjugate J.* 1997, 14:S44
36. Lo *et al.*, *Glycobiology* (1998), 8:517-526
37. Yang, Ji-Mao *et al.* *Glycobiology* 4:(6)873-884, 1994
38. Sutherlin, Marie E. *et al.*, (1997) *Cancer Research*, 57:4744-4748
39. Uehara, K. and Muramatsu, T. (1997) *Eur. J. Biochem.*, 244:706-712

EXAMINER: \_\_\_\_\_

DATE CONSIDERED: \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.